^
    No biomarker
    Rhabdomyosarcoma
    dactinomycin
    Sensitive: A1 - Approval
    No biomarker
    Rhabdomyosarcoma
    IE
    Sensitive: A2 - Guideline
    No biomarker
    Rhabdomyosarcoma
    VAC
    Sensitive: A2 - Guideline
    No biomarker
    Rhabdomyosarcoma
    doxorubicin hydrochloride + cyclophosphamide + etoposide IV + vincristine
    Sensitive: A2 - Guideline
    No biomarker
    Rhabdomyosarcoma
    trabectedin
    Sensitive: A2 - Guideline
    No biomarker
    Rhabdomyosarcoma
    ADX-2191
    Sensitive: A2 - Guideline
    No biomarker
    Rhabdomyosarcoma
    vinorelbine
    Sensitive: A2 - Guideline
    No biomarker
    Rhabdomyosarcoma
    topotecan
    Sensitive: A2 - Guideline
    No biomarker
    Rhabdomyosarcoma
    irinotecan
    Sensitive: A2 - Guideline
    No biomarker
    Rhabdomyosarcoma
    SA033
    Sensitive: A2 - Guideline
    No biomarker
    Rhabdomyosarcoma
    temozolomide + irinotecan + vincristine
    Sensitive: A2 - Guideline
    No biomarker
    Rhabdomyosarcoma
    cyclophosphamide + vinorelbine tartrate
    Sensitive: A2 - Guideline
    No biomarker
    Rhabdomyosarcoma
    carboplatin + etoposide oral
    Sensitive: A2 - Guideline
    No biomarker
    Rhabdomyosarcoma
    vincristine + dactinomycin
    Sensitive: A2 - Guideline
    No biomarker
    Rhabdomyosarcoma
    irinotecan + vincristine
    Sensitive: A2 - Guideline
    No biomarker
    Rhabdomyosarcoma
    doxorubicin hydrochloride + ifosfamide
    Sensitive: A2 - Guideline
    No biomarker
    Rhabdomyosarcoma
    cyclophosphamide + topotecan
    Sensitive: A2 - Guideline
    No biomarker
    Rhabdomyosarcoma
    doxorubicin hydrochloride + ifosfamide + vincristine
    Sensitive: A2 - Guideline
    No biomarker
    Rhabdomyosarcoma
    doxorubicin hydrochloride + ifosfamide + cyclophosphamide + vincristine
    Sensitive: A2 - Guideline
    PD-L1 expression
    Rhabdomyosarcoma
    nivolumab
    Sensitive: C1 - Off-label
    BRAF-MAD1L1 fusion
    Rhabdomyosarcoma
    anlotinib
    Resistant: C4 – Case Studies
    PD-L1 expression
    Rhabdomyosarcoma
    pazopanib
    Resistant: C4 – Case Studies
    HRAS mutation
    Rhabdomyosarcoma
    tipifarnib
    Sensitive: D – Preclinical
    KDM1A overexpression
    Rhabdomyosarcoma
    SP2577
    Sensitive: D – Preclinical
    PAX3-FOXO1 fusion
    Rhabdomyosarcoma
    SNDX-275
    Sensitive: D – Preclinical
    HER-2 expression
    Rhabdomyosarcoma
    T-lymphocyte cell therapy
    Sensitive: D – Preclinical